Synthesis and Evaluation of 5-Phenyl-1*H***-1,4-benzodiazepin-2(3***H***)-one-Based Palladium Complexes as Precatalysts in C**-**C Bond Forming Reactions**

John Spencer,*,† David P. Sharratt,† Jairton Dupont,‡ Adriano L. Monteiro,‡ Vinicius I. Reis,‡ Marcelo P. Stracke,‡ Frank Rominger,§ and Iain M. McDonald†

James Black Foundation, 68 Half Moon Lane, London, SE24 9JE, U.K., Laboratory of Molecular Catalysis, IQ-UFRGS, Avenida Bento Gonçalves, 9500, Porto-Alegre 91501-970 RS, Brazil, and Organisch-Chemishes Institut der Ruprecht-Karls-Universita¨*t Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany*

Received August 1, 2005

The C-H activation of C-3-unsubstituted 1,4-benzodiazepin- $2(3H)$ -ones (LH = $2a-c$) ($2a$ $= 1$ -methyl-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one, **2b** = 1-benzyl-5-phenyl-1*H*-1,4-benzodiazepin-2($3H$)-one, $2c = \text{benzyl-2-(2,3-dihydro-2-oxo-5-phenyl-1,4-benzodiazepin-1-yl)}$ acetate) with Na_2PdCl_4 afforded the insoluble palladacycles $[(L)\text{PdCl}_2]$ **3a-c**. Treatment of the latter with triphenylphosphine afforded the soluble monomeric triphenylphosphine analogues $[(L)Pd(PPh₃)C]$ **4a-c**. 1-Methyl-3-(2-(methylthio)ethyl)-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (LH = 2d) reacted with Na_2PdCl_4 or with $\text{PdCl}_2(\text{MeCN})_2$ to afford the monomeric *cis*-S-N-coordinated complex **5d** of the type [(LH)PdCl₂]. 3-((*tert*-Butylthio)methyl)-1-methyl-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one, **2e**, reacted with $Pd(OAc)_2$ in acetic acid and, following LiCl metathesis, yielded the monomeric *cis*-S-N-bound pincer palladacycle **6f**. X-ray structures of **5d** and **4a** have been determined. **3a** and **6f** were found to be effective precatalysts for Suzuki coupling reactions, and **3a**, **3c**, and **4a** were effective precatalysts in Heck couplings across a range of substrates.

Introduction

Palladacycles are a fascinating family of organometallic complexes with applications in many areas including total synthesis, materials science, and biological and supramolecular chemistry.¹ Moreover, they are often air stable, are readily synthesized, and possess a range of structures, ring sizes, types of metalated carbon $(sp²]$ aromatic or vinylic, sp^3), and different types of donor groups bound to palladium (P-, N-, S-, O-, Se-containing groups) (Figure 1). The stoichiometric applications of palladacycles in organic synthesis have been reviewed,2 and an increasing number of attractive high turnover number (TON) catalytic applications are now known.^{3,4}

The coordination chemistry of the pharmaceutically

(3) Reviews: (a) Herrmann, W. A.; Bohm, V. P. W.; Reisinger, C. P. *J. Organomet. Chem*. **1999**, *576*, 23. (b) Bedford, R. B. *Chem Commun*. **2003**, 1787. (c) Dupont, J.; Pfeffer, M.; Spencer, J. *Eur. J. Inorg. Chem*. **2001**, 1917. (d) van der Boom, M. E.; Milstein, D. *Chem. Rev.* **2003**, *103*, 1759. (e) Beletskaya, I. P.; Cheprakov, A. V. *J. Organomet. Chem*. **2004**, *689*, 4055. (f) Farina, V. *Adv. Synth. Catal*. **2004**, *346*, 1553. (g) Bellina, F.; Carpita, A.; Rossi, R. *Synthesis* **2004**, *15*, 2419. (h) Zapf, A.; Beller, M. *Chem. Commun*. **2005**, 431. (i) Bedford R. B.; Cazin, C. S. J.; Holder, D. *Coord. Chem. Rev*. **2004**, *248*, 2283.

important 1,4-benzodiazepine skeleton has been studied in detail,5 and it has been shown to act as a bidentate or monodentate ligand toward palladium. For example, the palladacycle \bf{A} resulted from the $\bf{C}-\bf{H}$ activation of the $C(5)$ phenyl group in Valium using $Na₂PdCl₄$ as metallating agent, whereas the coordination complex **B** was synthesized using Prazepam as ligand and PdCl₂- $(PhCN)_2$ as palladium source. Complex \bf{A} was employed in a carbonylation reaction yielding the novel heterocycles **C** (Scheme 1).5a,b

We recently prepared a range of C-3-unsubstituted 1,4-benzodiazepine ligands as precursors to imine-bound palladacycles related to **^A** employing similar C-^H

 $*$ Corresponding author. Fax $+$ 44-207-2749687. E-mail: john.spencer@kcl.ac.uk.

[†] James Black Foundation.

[‡] Laboratory of Molecular Catalysis, IQ-UFRGS.

[§] Organisch-Chemishes Institut der Ruprecht-Karls-Universität Heidelberg.

⁽¹⁾ Dupont, J.; Consorti, C. S.; Spencer, J. *Chem. Rev.* **2005**, *105*, 2527.

^{(2) (}a) Ryabov, A. D. *Synthesis* **1985**, 233. (b) Spencer, J.; Pfeffer, M. *Adv. Met. Org. Chem*. **1998**, *6*, 103. (c) Omae, I. *Coord. Chem. Rev.* **2004**, *248*, 995.

^{(4) (}a) Xiong, Z.; Wang, N.; Dai, M.; Li, A.; Chen, J.; Yang, Z. *Org. Lett.* **2004**, *6*, 3337. (b) Botella, L.; Najera, C. *Tetrahedron* **2004**, *60*, 5563. (c) Schnyder, A.; Indolese, A. F.; Studer, M.; Blaser, H. U. *Angew.*
Chim. Int. Ed. 2002, 41, 3668 (d) Yao, Q.; Kinney, E. P.; Zheng, C.
Org. Lett. 2004, 6, 2997. (e) Roca, F. X.; Richards, C. J. *Chem. Commun. Tetrahedron Lett.* **2004**, *45*, 2915. (g) Chen, C.-L.; Liu, Y. H.; Peng, S. M.; Liu, S.-T. *Organometallics* **2005**, *24*, 1075. (h) Eberhard, M. R. *Org. Lett*. **2004**, *6*, 2125. (i) Bielsa, R.; Larrea, A.; Navarro, R.; Soler, T.; Urriolabeitia, E. P. *Eur. J. Inorg. Chem*. **2005**, 1724. (j) Rocaboy, C.;

Gladysz, J. A. *New J. Chem.* **2003**, *27*, 39. (5) (a) Cinellu, M. A.; Gonadu, M. L.; Minghetti, G.; Cariati, F.; Manasserro, M. *Inorg. Chim. Acta* **1988**, *143*, 197. (b) Cinellu, M. A.; Gladiali, S.; Minghetti, G.; Stoccorro, S.; Demartin, F. *J. Organomet.
Chem.* **1991**, 401, 371. (c) Perez, J.; Riera, V.; Rodriguez, A.; Miguel,
D. *Organometallics* **2002**, 21, 5437. (d) Visnjevac, A.; Tusek,-Bozic, L.; Majeric-Elenkov, M.; Hamersak, Z.; Kooijman, H.; De Clercq, E.; Kojic-Prodic, B. *Polyhedron* **2002**, *21*, 2567. (e) Antolini, L.; Bruno, G.; Cusumano, M.; Giannetto, A.; Ficarra, P.; Ficarra, R. *Polyhedron* **1992**, *11*, 2795. (f) Cusumano, M.; Giannetto, A.; Ficarra, P.; Ficarra, R. *J. Chem. Soc., Dalton Trans*. **1991**, 1581. (g) Stoccoro, S.; Cinellu, M. A.; Zucca, A.; Minghetti, Demartin, F. *Inorg. Chim. Acta* **1994**, *215*, 17.

Figure 1. Examples of palladacycles employed in catalysis.

Scheme 1. Palladium-Containing 1,4-Benzodiazepine Complexes and a Carbonylation Reaction

activation reactions. Intrigued by the possibility of a tridentate binding mode to palladium, C-3-substituted 1,4-benzodiazepine ligands were synthesized by introducing a side chain containing a thioether group, derived from either cysteine or methionine. Herein we present results pertaining to the synthesis of 1,4 benzodiazepine-containing palladium complexes, their structural characterization in both solution and the solid state, and their application in catalysis.

Results and Discussion

1,4-Benzodiazepine Synthesis. The 1,4-benzodiazepines **1a**-**^e** were made by a modification of the reported methods ($EEDQ = 2$ -ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline).6 Alkyl substituents at the N-1 position were introduced by treatment with sodium hydride and reaction with the requisite alkyl halides, affording $2a-e$, which were characterized by ¹H, ¹³C NMR and LCMS (Scheme 2).

Palladium Complexes. Treatment of **2a**-**^c** with Na2PdCl4 in ethanol resulted in the formation of yellow or beige precipitates. Due to their low solubility, it was not possible to satisfactorily characterize these products by 1H NMR spectroscopy. However, their treatment with triphenylphosphine afforded soluble products, whose spectral properties, particularly the shielded aromatic protons in their 1H NMR spectra, characteristic of a metalated phenyl group *cis* to PPh₃, and a ³¹P NMR singlet at ca. 41 ppm, were consistent with the monomeric structures $4a-c$ ⁷ By inference, the original
precipitates were assigned the dimeric structures $3a$ precipitates were assigned the dimeric structures **3ac**, which were, moreover, consistent with the combustion data obtained (Scheme 3).

The solid-state structure of the palladacycle **4a** was determined by an X-ray study of crystals obtained from a dichloromethane/hexane mixture. The palladacycle was found to have a distorted square planar configuration, probably as a result of steric encumbrance from the triphenylphosphine ligand, resulting in a C1-Pd-Cl1 bond angle of $171.84(7)$ ° and a N1-Pd-P1 angle of 174.92(6)° (Table 1, Figure 2). Bond lengths in **4a** were found to be similar to those in related

^{(6) (}a) Stafford, J. A.; Pacofsky, G. J.; Cox, R. F.; Cowan, J. R.; Dorsey, G. F.; Gonzales, S. S.; Jung, D. K.; Koszalka, G. W.; McIntyre, M. S.; Tidwell, J. H.; Wiard, R. P.; Feldman, P. L. *Bioorg. Med. Chem. Lett*. **2002**, *12*, 3215. (b) Clarke, G. M.; Lee, G. M.; Swinbourne, F. J.; Williamson, B. *J. Chem. Res.* **1980**, *12*, 4777. (c) Carpino, L. A.; Cohen, B. J.; Stephens, K. E., Jr.; Sadat-Aalaee, S. Y.; Tien, J. H.; Langridge, D. C. *J. Org. Chem.* **1986**, *51*, 3732. (d) Marc, G.; Pecar, S. *Synth. Commun*. **1998**, *28*, 1143, and references therein.

⁽⁷⁾ Dunina, V. V.; Kuz'mina, L. G.; Rubina, M. Y.; Grishin, Y. K.; Veits, Y. A.; Kazakova, E. I. *Tetrahedron: Asymmetry* **1999**, *10*, 1483, and references therein.

Scheme 2. 1,4-Benzodiazepine Synthesis

i) (FMOC)NHCH(R₂)CO₂H, EEDQ, THF, 16h. ii) Et₂NH, MeCN, 2h. iii) SiO₂ chromatography. iv) NaH, R_1 Br or R_1 I

Scheme 3. 1,4-Benzodiazepine Palladation

Table 1. Selected Bond Lengths (Å) and Angles

Figure 2. ORTEP diagram of **4a** (hydrogen atoms omitted for clarity).

palladacycles,5b,9a and the Pd-Cl bond length of 2.3602- (7) Å reflects the high *trans* influence of the metalated carbon atom.

Scheme 4. Synthesis of the Coordination Complex 5d

2a; $R_1 = CH_3$, $R_2 = H$

2b; $R_1 = Bn$, $R_2 = H$

2c; $R_1 = CH_2CO_2Bn$, $R_2 = H$

2d; $R_1 = CH_3$, $R_2 = (CH_2)_2$ SCH₃ 2e; $R_1 = CH_3$, $R_2 = CH_2St$ -Bu

Treatment of the sulfur-containing 1,4-benzodiazepine 2d with Na₂PdCl₄, according to the same conditions used to obtain **3a**-**c**, afforded a precipitate, which was sufficiently soluble for 1H NMR characterization. In the product, S-Pd coordination was evidenced by a significant ¹H NMR downfield shift of the SMe signal (δ = 2.76 ppm) compared with the free ligand ($\delta = 2.06$) ppm).8 An identical product was obtained after treatment of 2d with PdCl₂(MeCN)₂, suggesting the chelatedmonomeric structure **5d**, which was unequivocally determined by a single-crystal X-ray structure measurement (Scheme 4, Figure 3).

Crystals of **5d** were grown from a chloroform/hexane mixture and were found to be racemic and to contain a molecule of chloroform in the asymmetric unit. The unit cell contains eight molecules of $CHCl₃$. There is no $Pd-C$ bond, and the metal is part of a six-membered boatshaped ring with a *cis-*S,N arrangement (Figure 3 and Table 2). The Pd-Cl bond lengths of around 2.33 Å are as expected. In the absence of a bulky phosphine ligand, the anticipated square planar arrangement is less distorted than in **4a**, with bond angles including N1- Pd-S1 of $90.95(9)$ ° and S1-Pd-Cl2 of 176.33(4)°.

In an attempt to form a palladacycle analogue by ^C-H activation chemistry, **2d** was reacted with Pd- $(OAc)_2$ in acetic acid followed by LiCl metathesis. However, 1H NMR analysis of the crude reaction mixture revealed the presence of more than one species in solution. Hence, we concentrated our efforts on the corresponding reaction of the cysteine-derived 1,4 benzodiazepine **2e**. Reaction of the latter with $Pd(OAc)_2$ afforded the acetate analogue **6e**, evidenced by the presence of only eight aromatic protons, a singlet for a single acetate group, and a downfield shift of 0.3 ppm

^{(8) (}a) Ebeling, G.; Meneghetti, M. R.; Rominger, F.; Dupont, J. *Organometallics* **2000**, *21*, 3221. (b) Dupont, J.; Gruber, A. S.; Fonseca, G. S.; Monteiro, A. L.; Ebeling, G.; Burrow, R. A. *Organometallics* **2001**, *20*, 171. (c) Spencer, J.; Pfeffer, M.; Kyritsakas, N.; Fischer, J. *Organometallics* **1995**, *14*, 2214.

^{(9) (}a) Bedford, R. B.; Cazin, C. S. J.; Hursthouse, M. B.; Light, M. E.; Pike, K. J.; Wimperis S. *J. Organomet. Chem*. **2001**, *633*, 173. (b) Bedford, R. B.; Cazin, C. S. J.; Hursthouse, M. B.; Light, M. E.; Scordia, V. J. M. *J. Chem. Soc., Dalton Trans.* **2004**, 3864. (c) Louie, J.; Hartwig, J. F. *Angew. Chim. Int. Ed.* **1996**, *35*, 2359. (d) Nowotny, M.; Hanefeld, U.; van Koningsveld, H.; Maschmeyer, T. *Chem. Commun.* **2000**, 1877.

Figure 3. ORTEP diagram of **5d** (hydrogen atoms, with the exception of (H2), omitted for clarity).

Bond Lengths						
$Pd1-N1$	2.055(3)	$Pd1-S1$	2.2858(10)			
$Pd1 - Cl1$	2.3301(9)	$Pd1 - Cl2$	2.3445(8)			
$S1 - C9$	1.815(4)	$S1 - C10$	1.820(5)			
$N1 - C7$	1.297(5)	$N1 - C2$	1.489(5)			
Bond Angles						
$N1-Pd1-S1$	90.95(9)	$C9 - S1 - C10$	99.0(2)			
$N1-Pd1-Cl1$	177.77(9)	$C9 - S1 - Pd1$	103.73(15)			
$S1-Pd1-C11$	88.48(4)	$C10-S1-Pd1$	106.24(18)			
$N1-Pd1-Cl2$	89.24(9)	$C7-N1-C2$	116.7(3)			
$S1-Pd1-C12$	176.33(4)	$C7-N1-Pd1$	123.7(2)			
$Cl1-Pd1-Cl2$	91.47(3)	$C2-N1-Pd1$	119.1(2)			

Scheme 5. Synthesis of the Palladacycles 6e and 6f

of the S*t-*Bu group compared with **2e**, attributed to an S-Pd bond, in its ¹H NMR spectrum.⁸ The chloro analogue **6f** was formed by a metathesis reaction with excess LiCl in acetone.

Carbon-**Carbon Bond Forming Reactions Mediated by 3**-**6.** Palladacycles are well-established precatalysts in Suzuki and Heck reactions, acting, after activation, as a source of catalytically active $Pd(0).^{1,3}$ As a preliminary assessment of the use of palladacycles **³**, **⁴**, and **⁶** in C-C bond forming reactions, we found that the reaction of **3a** with excess 3-tolylboronic acid afforded the ortho-arylated benzodiazepine **7a** as the main product (Scheme 6).9

This result suggested that **3a** could act as a source of Pd(0), and accordingly, it was found to be an effective precatalyst (0.5 mol % Pd) for the Suzuki coupling of phenylboronic acid with the electron-rich (poor coupling

partner) 4-bromoanisole, affording 4-methoxybiphenyl in 90% yield (100% consumption of 4-bromoanisole, entry 1, Table 3). Building on the promising activity of **3a** we tested other derivatives for catalytic activity in the same reaction, which is often used as a benchmark for catalytic performance.1 Palladacycle **6f** had a catalytic performance similar to **3a** (87% yield of 4-methoxybiphenyl, entry 7), and the coordination complex **5d** had good activity (81% yield of 4-methoxybiphenyl, entry 5). The latter result is not surprising, as the related Pd(II) coordination complexes $PdCl₂(SEt₂)₂$ ^{10a} and $Pd(OAc)₂$ ^{10a-c} as well as other complexes,^{3f} including $[Pd(NCOC₂H₄CO)(PPh₃)₂Br]$,^{10d} are also effective precatalysts for this type of transformation.

The reaction was also carried out over shorter reaction times (2 h), and complex **6f** was the most effective precatalyst, with a high yield of 4-methoxybiphenyl (92%) observed (entry 8). Attempts to use lower catalyst loadings of **3a** and **6f**, over 27 h, led to moderate TONs, 1620 with **3a** (entry 4) and 1440 with **6f** (entry 9), which are far inferior to many of the known palladacycle systems.^{1,3}

3a (0.5 mol % Pd) was tested in Suzuki coupling reactions of aryl chlorides with phenylboronic acid under the same conditions. Using the deactivated substrate, 4-chloroanisole, only a 4% yield of 4-methoxybiphenyl was obtained, and with a more activated halide, 4-chloroacetophenone, a modest conversion (56%) and yield (34%) of 4-phenylacetophenone were observed. Changing the base $(K_2CO_3, K_3PO_4, n-Bu_4NBr)$ and/or solvent (DMA, DMF, *o*-xylene) did not improve the coupling of $PhB(OH)₂$ with 4-chloroacetophenone. The use of a phosphine as a co-ligand in palladacycle-mediated coupling reactions has been described.4c,11 Hence, when we combined PCy_3 with **3a** (0.5 mol $%$ Pd) for the coupling of $PhB(OH)_2$ with 4-chloroacetophenone, quantitative consumption of 4-chloroacetophenone was observed and an 81% isolated yield of 4-phenylacetophenone was found. Under identical conditions, with the deactivated substrate, 4-chloroanisole, a 41% conversion of the starting chloride was observed, along with a 38% yield of 4-methoxybiphenyl (Scheme 7).

In line with our earlier studies, we have also probed the catalytic activity of some of the above complexes in the Heck reaction of various aryl halides and alkenes.¹² The soluble and well-defined monomeric complex **4a** was selected and compared with the dimeric, less soluble, phosphine-free precursors **3a** and **3c**.

As an initial point of comparison, the three selected palladacycles were tested as precatalysts for the coupling of olefins with the, less-reactive, electron-rich aryl halides and in particular aryl bromides. As can be seen from Table 4, good activity was observed, and as expected, aryl iodides were more reactive than their bromo congeners.4a,12 For example, a 97% yield of (*E*) butyl 3-*p*-tolylacrylate was observed with 4-iodotoluene

^{(10) (}a) Gruber, A. S.; Pozebon, D.; Monteiro, A. L.; Dupont, J. *Tetrahedron Lett*. **2001**, *42*, 7345. (b) Yao, Q.; Kinney, E. P.; Yang, Z. *J. Org. Chem*. **2003**, *68*, 7528. (c) de Vries, A. H. M.; Mulders, J. M. C. A.; Mommers, J. H. M.; Henderickx, H. J. W.; de Vries, J. G. *Org. Lett.* **2003**, *5*, 3285. (d) Fairlamb, I. J. S.; Kapdi, A. R.; Lynam, J. M.; Taylor, R. J. K.; Whitwood, A. C. *Tetrahedron* **2004**, *60*, 5711.

⁽¹¹⁾ Bedford, R. B.; Cazin, C. S. J.; Hazelwood (née Welsh), S. L. *Chem. Commun*. **2002**, 2608.

⁽¹²⁾ Gruber, A. S.; Zim, D.; Ebeling, G.; Monteiro, A. L.; Dupont, J*. Org. Lett.* **2000**, *2*, 1287.

L=ligand or vacant site

Table 3. Suzuki Coupling of 4-Bromoanisole and PhB(OH)2 with Palladacycles 3a and 6f or Complex 5d

MeO	Br $\ddot{}$	[Pd] $B(OH)_2$ CsF, 130°C dioxan, 27h or 2h	OMe
entry	$3 \pmod{ \% }$ [Pd])	yield ^{<i>a</i>} (conversion) ^{<i>b</i>}	reaction time (h)
1	3a(0.5)	90(100)	27
$\overline{2}$	3a(0.5)	71 (94)	$\boldsymbol{2}$
3	3a(0.2)	86 (100)	27
$\overline{4}$	3a(0.05)	81 (100)	27
5	5d(0.5)	81 (100)	27
6	5d(0.5)	59 (74)	$\boldsymbol{2}$
7	6f(0.5)	87 (98)	27
8	6f(0.5)	92 (100)	2
9	6f(0.05)	72 (92)	27
10	6f(0.005)	15(43)	27

^a GC yield of 4-methoxybiphenyl (using undecane as an internal standard). *^b* GC conversion of 4-bromoanisole (using undecane as an internal standard).

Scheme 7. Suzuki Coupling of 4-Chloroarenes with $PhB(OH)₂$ Catalyzed by 3a

as substrate, using **3a** as precatalyst (entry 1, Table 4), whereas with its bromo analogue a lower yield of product (74%) was observed (entry 4). A similar trend was observed when employing **3c** as precatalyst, where a 91% yield of coupled product was observed using 4-iodotoluene as aryl halide (entry 2) versus a 57% yield with 4-bromotoluene (entry 5). The palladacycles **3c** and **4a** gave lower yields of coupling product than **3a**; for example, the yield of (*E*)-butyl 3-*p*-tolylacrylate was 91% (**3c**, entry 2) and 90% (**4a**, entry 3) compared with 97% (**3a**, entry 1), and this trend was repeated for the formation of (*E*)-butyl cinnamate from bromobenzene (compare entries 6-8). Gratifyingly, (*E*)-stilbene analogues were formed in good yields from the coupling of styrene with aryl bromides mediated by **3a** (entries 10 and 11).

Electron-poor (activated) aryl bromides readily coupled with *n*-butylacrylate in the presence of **3a**, **3c**, or **4a** (Table 5). The palladacycle **3c** afforded better yields for the coupling of *n*-butylacrylate with 4-acetobromobenzene (89%, entry 2) and 4-cyanobromobenzene (82%, entry 5) than **3a** (71%, entry 1, 70%, entry 4, respectively). With the palladacycle **4a**, for the coupling of *n*-butylacrylate with 4-acetobromobenzene, a 64% yield was observed (entry 3), whereas with 4-cyanobromobenzene, a 90% yield was observed (entry 6). In the case of

Table 4. Heck Coupling Reactions of Electron-Rich Aryl Halides and Olefins

^a Reaction conditions: 0.1 mol % [Pd], DMA (5 mL), NaOAc (1.4 mmol), alkene (1.2 mmol), ArX (1 mmol), and *n-*Bu4NBr (0.2 mmol), 120 °C, 24 h (time after which the reaction was analyzed). *^b* GC yield in (*E*)*-*butyl 3-arylacrylate or (*E*)*-*stilbenes (using undecane as an internal standard). *^c* GC conversion. *^d* Isolated yield.

Table 5. Heck Coupling Reactions of Electron-Poor Aryl Halides with *n***-Butyl Acrylate**

۰x Ar		CO ₂ n-Bu	Ar	
		0.1 mol% [Pd], DMA, NaOAc n-Bu ₄ NBr. 120°C, 24h.		$CO2n$ -Bu
$entry^a$	[Pd]	ArX	yield $(\%)^b$	conversion $(\%)^c$
1	Зa	$4-MeCOC6H4Br$	71	91
$\overline{2}$	$3\mathbf{c}$	$4-MeCOC6H4Br$	$89 (89%)^d$	91
3	4a	$4-MeCOC6H4Br$	64	90
$\overline{\mathbf{4}}$	3a	4 -CNC $_6$ H ₄ Br	70	85
5	3c	4 -CNC $_6$ H ₄ Br	82	90
6	4a	4 -CNC $_6$ H ₄ Br	90	90
7	3a	$4-NO2C6H4Br$	96	99
8	3c	$4-NO2C6H4Br$	83	86
9	4a	$4-NO2C6H4Br$	70	91
10	3a	$4-CF_3C_6H_4Br$	98	98
11	$_{\rm 3c}$	$4-CF_3C_6H_4Br$	94	98
12	4a	$4-CF3C6H4Br$	69	90
13	3a	$4-MeCOC6H4Cl$	31	45
14^e	3a	4-MeCOC ₆ H ₄ Cl	8	12

^a Reaction conditions: 0.1 mol % [Pd], DMA (5 mL), NaOAc (1.4 mmol), alkene (1.2 mmol), ArX (1 mmol), and *n*-Bu4NBr (0.2 mmol), 120 °C, 24 h (time after which the reaction was analyzed). *^b* GC yield in (*E*)*-*butyl 3-arylacrylate or (*E*)*-*stilbenes (using undecane as an internal standard). *^c* GC conversion. *^d* Isolated yield. *^e* At 150 °C.

4-nitrobromobenzene, yields of coupling product with *n*-butylacrylate were higher with **3a** (96%, entry 7) than with **3c** (83%, entry 8) or **4a** (70%, entry 9). A similar trend was observed for the coupling of *n*-butylacrylate with 4-trifluoromethylbromobenzene (98%, **3a**; 94%, **3b**; 69% , **4a**, respectively, entries $10-12$). As with the Suzuki coupling reactions (Table 3), activated chlorides were poor coupling partners and yields were worse at elevated temperatures (entries 13 and 14, Table 5). In a few cases isolated yields were obtained and were in agreement with those determined by GC (entry 1, Table 4, and entry 2, Table 5).

Conclusion

We have demonstrated that the 1,4-benzodiazepine system is a modular and versatile ligand for the preparation of palladium complexes. Air-stable palladacycles **3a**-**^c** and the "SCN pincer"13 palladacycle **6f** were prepared by C-H activation reactions, and the reaction of **3a**-**^c** with PPh3 led to the monomeric **4ac**. The novel monomeric coordination complex **5d** was formed from the reaction of $2d$ with $Na₂PdCl₄$ or $PdCl₂$ -(MeCN)2. ¹⁴ Complexes **3a** and **6f** displayed moderate activity in Suzuki coupling reactions, whereas **3a**, **3c**, and **4a** had moderate activity in Heck couplings, which may be due to poor catalyst longevity.^{3b} Future studies will be aimed at preparing 1,4-benzodiazepine-containing complexes to address this issue.

Experimental Section

General Procedures. All procedures were carried out in air using commercial high-grade solvents (Fluka & Aldrich Sureseal). Palladium salts were purchased from Aldrich and used without further purification. Amino acids and coupling agents were purchased from Novabiochem. ${}^{1}H$, ${}^{13}C{}^{1}H$, and $31P{1}H$ NMR spectra were recorded on a Bruker AC 300 spectrometer at 300, 75, and 120 MHz, respectively. Mass spectra were carried out on a Waters ZQ spectrometer. Optical activity measurements were recorded with a sodium lamp at 589 nM at 20 °C on an Optical Activity A10 polarimeter. Elemental analyses were carried out by the Cambridge University Microanalysis Service. Flash chromatography was carried out on silica gel (Merck silica 60 (0.040-0.064 mm grade)). Catalytic test reactions were performed as described previously.12,15

Synthesis. 5-Phenyl-1*H***-1,4-benzodiazepin-2(3***H***)-one, 1a.** 2-Aminobenzophenone (1.18 g, 6.00 mmol), EEDQ (1.48 g, 6.00 mmol), and FMOC-Gly-OH (1.78 g, 6.00 mmol) were combined in anhydrous THF (25 mL) and left to stir at room temperature overnight. After dilution with ethyl acetate (40 mL) and successive washings with potassium hydrogen sulfate solution (10%, 20 mL), saturated sodium hydrogen carbonate (20 mL) , and brine, the organic layer was dried $(MgSO₄)$, filtered, and concentrated. The crude product was treated with a 20% solution of diethylamine in acetonitrile (30 mL) at room temperature for 2 h. After evaporation of the volatiles followed by flash chromatography (70:30 ethyl acetate/hexane) an oil was obtained (0.99 g, 70%). 1H NMR (CDCl3): *δ* 8.65 (1H, s), 7.56-7.35 (7H, m), 7.19 (2H, m), 4.34 (2H, s). 13C NMR

(15) (a) Rosa, G. R.; Ebeling, G.; Dupont, J.; Monteiro, A. L. *Synthesis* **2003**, *18*, 2894. (b) Zim, D.; Gruber, A. S.; Ebeling, G.; Dupont, J.; Monteiro, A. L. *Org. Lett*. **2000**, *2*, 2881.

(CDCl3): *δ* 172.9, 171.6, 139.9, 139.3, 132.1, 131.7, 130.7, 130.1, 128.5, 127.6, 123.6, 121.7, 57.1. (C15H12N2O); *^m*/*^z* 237 (MH+, 100%). Alternatively, the method of Stafford *et al.* was used.^{6a}

1-Methyl-5-phenyl-1*H***-1,4-benzodiazepin-2(3***H***)-one, 2a.**6b The product from the previous step (0.50 g, 2.12 mmol) was stirred with sodium hydride (60% suspension in paraffin oil, 0.12 g, 3.00 mmol) in DMF (10 mL) for 0.5 h under Ar. Thereafter, iodomethane (264 *µ*L, 4.24 mmol) was added and the reaction was monitored by TLC until complete. After dilution with ethyl acetate (30 mL), the organic layer was washed with brine $(2 \times 30 \text{ mL})$ and water (20 mL) , dried (MgSO4), filtered, and concentrated in vacuo. The product was obtained as a solid after column chromatography (7:3 ethyl acetate/pentane) (0.47 g, 48%). 1H NMR (CDCl3): *^δ* 7.63-7.16 (9H, m), 4.83 (1H, d), 3.81 (1H, d), 3.41 (3H, s). 13C NMR (CDCl3): *δ* 170.8, 170.5, 144.5, 139.2, 131.7, 130.9, 130.7, 129.9, 128.6, 124.1, 121.4, 57.4, 35.2 (C16H14N2O); *^m*/*^z* 251 (MH+, 100%).

1-Benzyl-5-phenyl-1*H***-1,4-benzodiazepin-2(3***H***)-one, 2b.** This was made on a 0.5 mmol scale (0.163 g, 55%) according to the method used for the synthesis of **2a** except that benzyl bromide was used instead of methyl iodide. 1 H NMR (CDCl₃): δ 7.47-7.06 (14H, m), 5.63 (1H, d, $J(HH) = 15.3$ Hz), 4.89 (1H, d, $J(HH) = 10.2$ Hz), 4.79 (1H, d, $J(HH) = 15.3$ Hz), 3.90 (1H, d, $J(HH) = 10.2$ Hz). ¹³C NMR (CDCl₃): δ 171.0, 169.8, 142.6, 139.2, 137.2, 131.6, 130.9, 130.7, 130.6, 129.9, 129.0, 128.5, 127.8, 127.6, 124.8, 122.7, 57.4, 50.0 (C₂₂H₁₈N₂O); *m/z* 327 $(MH+, 100\%).$

Benzyl 2-(2,3-dihydro-2-oxo-5-phenyl-1,4-benzodiazepin-1-yl)acetate, 2c. This was made on a 1.9 mmol scale (0.364 g, 50%) according to the method used for the synthesis of **2a** except that benzyl bromoacetate was used instead of methyl iodide. ¹H NMR (CDCl₃): δ 7.61-7.20 (14H, m), 5.28 (2H, s), 4.85 (1H, d), 4.69 (1H, d), 4.53 (1H, d), 3.88 (1H, d). 13C NMR (CDCl3): *δ* 171.0, 170.0, 169.2, 143.1, 135.6, 132.0, 131.0, 130.8, 130.0, 129.7, 128.9, 128.8, 128.6, 124.9, 121.5, 67.6, 56.8, 49.9 (C24H20N2O3); *^m*/*^z* 385 (MH+, 20%).

3-(*S***)-(2-(Methylthio)ethyl)-5-phenyl-1***H***-1,4-benzodiazepin-2(3***H***)-one, 1d. 1d** was made on a 6 mmol scale according to the method used for **1a** (0.99 g, 54%) except that (*L*)-FMOC-Met-OH was used instead of FMOC-Gly-OH. 1H NMR (CDCl3): *δ* 8.05 (1H, s), 7.53 (3H, m), 7.42 (4H, m), 7.15 $(2H, m)$, 3.81 (1H, dd, $J(HH) = 5.4$ Hz), 2.84 (1H, m), 2.53 (2H, m), 2.13 (3H, s).

3-(*S***)-1-Methyl-3-(2-(methylthio)ethyl)-5-phenyl-1***H***-1,4 benzodiazepin-2(3***H***)-one, 2d. 1d** was treated with sodium hydride followed by iodomethane, on a 0.62 mmol scale, as for the synthesis of **2b**. The product was obtained as an oil (0.17 g, 85%) after flash chromatography (3:1 dichloromethane/ethyl acetate): α_D^{293} (+93.8°, CH₂Cl₂, *c* 1). ¹H NMR (CDCl₃): δ 7.61-7.29 (8H, m), 7.17 (1H, m), 3.76 (1H, m), 3.40 (3H, s), 2.76- 2.43 (4H, m), 2.06 (3H, s). 13C NMR (CDCl3): *δ* 169.5, 167.6, 142.6, 137.7, 130.4, 129.3, 129.2, 128.6, 128.1, 127.2, 122.8, 120.2, 60.8, 34.1, 30.1, 29.7, 14.5 (C19H20N2OS); *^m*/*^z* 325 (MH+, 100%).

3-(*S***)-(***tert***-Butylthio)methyl)-5-phenyl-1***H***-1,4-benzodiazepin-2(3***H***)-one, 1e. 1e** was made on a 5.4 mmol scale according to the method used for **1a** (1.0 g, 60%) except that (*L*)-FMOC-Cys(*t*-Bu)-OH was used instead of FMOC-Gly-OH. ¹H NMR (CDCl₃): δ 10.36 (1H, s), 7.53-7.00 (9H, m), 3.72 (1H, t, $J(HH) = 6.6$ Hz), 3.43 (2H, m), 1.34 (9H, s).

3-(*S***)-(***tert***-Butylthio)methyl)-1-methyl-5-phenyl-1***H***-1,4-benzodiazepin-2(3***H***)-one, 2e. 2e** was made from **1e** on a 2.96 mmol scale according to the method used for **2a** (0.40 g, 40%): α_D²⁹³ (+93.0°, CH₂Cl₂, *c* 1). ¹H NMR (CDCl₃): *δ* 7.53-7.02 (9H, m), 3.61 (1H, t, $J(HH) = 5.1$ Hz), 3.33 (2H, m), 3.29 (3H, s), 1.23 (9H, s). 13C NMR (CDCl3): *δ* 170.3, 168.8, 144.0, 139.0, 131.8, 130.7, 130.1, 129.5, 128.6, 124.2, 121.7, 64.8, 42.7, 35.5, 31.4 (C21H24N2OS); *^m*/*^z* 353 (MH+, 25%).

Palladacycles $[(L)PdCl]_2$ 3a-c. Typically the ligand $2a - c$ was stirred with 0.9 equiv of $Na₂PdCl₄$ in EtOH (20 mL)

^{(13) (}a) Holton, R. A.; Nelson, R. V. *J. Organomet. Chem.* **1980**, *201*, C35. (b) Ebeling, G.; Meneghetti, M. R.; Rominger, F.; Dupont, J. *Organometallics* **2002**, *21*, 3221. (c) Dangel, B. D.; Godula, K.; Youn, S. W.; Sezen, B.; Sames, D. *J. Am. Chem. Soc.* **2002**, *124*, 11856.

⁽¹⁴⁾ For the formation of coordination complexes rather than palladacycles when employing $Na₂PdCl₄$ as metallating agent, see (a) Dunina, V. V.; Gorunova, O.; Kuz'mina, L. G.; Livantsov, M. V.; Grishin, Y. K. *Tetrahedron: Asymmetry* **1999**, *10*, 3951. (b) Zhao, Y.; Helliwell, M.; Joule, J. A. *Arkivoc* **2000**, *1*, 360.

Table 6. Crystal Data and Structure Refinement for 4a

empirical formula fw	$C_{34}H_{28}C1N_2OPPd$ 653.40	
cryst syst	tetragonal	
space group	P4 ₂ /n	
Z	8	
unit cell dimens	$a = 25.6119(4)$ Å	$\alpha = 90^{\circ}$
	$b = 25.6119(4)$ Å	$\beta = 90^{\circ}$
	$c = 9.6401(2)$ Å	$\nu = 90^{\circ}$
volume	$6323.61(19)$ Å ³	
density (calcd)	1.37 g/cm ³	
absorp coeff	0.75 mm^{-1}	
max, and min. transmn	0.93 and 0.77	
cryst shape	polyhedron	
cryst size	$0.36 \times 0.10 \times 0.10$ mm ³	
cryst color	yellow	
θ range for data collection	1.1 to 27.5 $^{\circ}$	
index ranges	$-33 \le h \le 33$,	
	$-33 \le k \le 32$	
	$-12 \leq l \leq 12$	
no. of reflns collected	64 4 21	
no. of indep reflns	$7274(R(int) = 0.0437)$	
no. of obsd reflns	5776 ($I > 2\sigma(I)$)	
no. of data/restraints/params	7274/0/362	
goodness-of-fit on F^2	1.11	
final R indices $(I > 2\sigma(I))$	$R1 = 0.030$, w $R2 = 0.081$	
largest diff peak and hole	0.79 and -0.56 e $\rm \AA^{-3}$	

for 48 h at room temperature. The precipitate was isolated by filtration, washed with further EtOH and then chloroform (10 mL each), and dried in vacuo. The complexes **3a**-**^c** were obtained in 70% yield and were too insoluble for NMR determinations.

3a: Anal. Calcd for $(C_{16}H_{13}CIN_2OPd)_2$ ·CHCl₃: C, 43.96; H, 3.02; N, 6.21. Found: C, 44.16; H, 3.12; N, 6.26. **3b**: Anal. Calcd for $(C_{22}H_{17}CIN_2OPd)_2 \cdot 0.5CHCl_3$: C, 51.28; H, 3.30; N, 5.30. Found: C, 51.21; H, 3.30; N, 5.30. **3c**: Anal. Calcd for $(C_{24}H_{19}CIN_2O_3Pd)_2$: C, 54.88; H, 3.65; N, 5.35. Found: C, 54.30; H, 3.61; N, 5.28 (too insoluble for purification).

Reaction of 3a-**c with Triphenylphosphine.** Equimolar quantities of PPh₃ and 3 were stirred in dichloromethane (10 mL) overnight. After filtration through Celite, the filtrate was concentrated in vacuo and hexane added to afford a precipitate. The latter was collected by filtration and dried in vacuo.

4a: 1H NMR (CDCl3): *^δ* 7.72-7.27 (19H, m), 7.09 (1H, m), 6.85 (1H, m), 6.58 (2H, m), 6.12 (1H, d, $J(HH) = 12.3$ Hz), 3.75 (1H, d, *J*(HH) = 12.3 Hz), 3.41 (3H, s). ³¹P (CDCl₃): δ 41 (s)

4b: ¹H NMR (CDCl₃): δ 7.83-7.40 (19H, m), 7.07 (5H, m), 6.92 (2H, m), 6.56 (2H, m), 6.18 (1H, dd, $J(HH) = 15.3$ Hz, $J(HH) = 3$ Hz), 5.38 (1H, d, $J(HH) = 12.0$ Hz), 4.95 (1H, d, $J(HH) = 15.3 \text{ Hz}$), 3.90 (1H, dd). ³¹P (CDCl₃): δ 41 (s).

4c: 1H NMR (CDCl3): *^δ* 7.83-7.32 (24H, m), 7.07 (1H, m), 6.85 (1H, m), 6.58 (2H, m), 6.18 (1H, dd, $J(HH) = 12.3$ Hz), 5.17 (2H, dd, $J(HH) = 12.3$ Hz), 4.73 (1H, d, $J(HH) = 15.3$ Hz), 4.42 (1H, d, $J(HH) = 15.3$ Hz), 3.86 (1H, d, $J(HH) = 12.3$ Hz). 31P (CDCl3): *δ* 41 (s).

Coordination Complex [(LH)PdCl2] 5d. This complex was made (0.080 g, 32%) by the method employed for **3**, using ligand **2d** $(0.17 \text{ g}, 0.53 \text{ mmol})$ and Na_2PdCl_4 $(0.147 \text{ g}, 0.5 \text{ mol})$ mmol): α_{D}^{293} (+52.0°, CH₂Cl₂, *c* 1). Anal. Calcd for C₁₉H₂₀Cl₂N₂-OPdS.CHCl3: C, 38.67; H, 3.41; N, 4.51. Found: C, 38.97; H, 3.60; N, 4.54. 1H NMR (300 MHz, CDCl3): *δ* 8.65 (5H, m), 7.45 $(1H, d, J(HH) = 8.4 \text{ Hz})$, 7.19 (3H, m), 3.97 (1H, m), 3.54 (1H, m), 3.49 (3H, s), 2.76-2.39 (5H, m), 2.61 (1H, m).

Palladacycle 6e. 2e (0.12 g, 0.34 mmol) and palladium acetate (0.070 g, 0.31 mmol) were stirred in acetic acid at 90 °C for 1 h. After cooling, the reaction mixture was filtered over Celite, then concentrated in vacuo. The resulting oil was washed with hexane and dried in vacuo. **6e** was obtained as a beige solid after crystallization from dichloromethane/hexane (0.15 g, 94%). 1H NMR (CDCl3): *δ* 7.69 (2H, m), 7.38 (2H, m),

7.17 (2H, m), 6.99 (2H, m), 4.27 (1H, d, $J(HH) = 6.6$ Hz), 3.38 (4H, m), 3.00 (1H, m), 2.05 (3H, brs), 1.51 (9H, s). Anal. Calcd for $C_{23}H_{26}N_2O_3PdS$: C, 53.44; H, 5.07; N, 5.42. Found: C, 53.04; H, 5.06; N, 5.23.

Palladacycle 6f. 6e (0.15 g, 0.29 mmol) was stirred with LiCl (0.085 g, 2.00 mmol) in acetone for 30 min. After evaporation of the volatiles, the resulting solid was extracted with dichloromethane $(3 \times 20 \text{ mL})$ and filtered over Celite. The filter cake was washed with acetone (30 mL), and the combined filtrates were concentrated in vacuo to one-tenth their volume. A beige solid was obtained by the addition of hexane, collected by filtration, and dried in vacuo (0.144 g) , 94%): α_{D}^{293} (+488.2°, CH₂Cl₂, *c* 0.5). Anal. Calcd for C₂₁H₂₃-ClN2OPdS'0.5acetone: C, 51.73; H, 5.02; N, 5.36. Found: C, 51.61; H, 4.74; N, 5.63. 1H NMR (CDCl3): *δ* 7.99 (1H, d, *J*(HH) $= 7.8$ Hz), 7.73 (2H, m), 7.40 (2H, m), 7.23 (1H, t, $J(HH) = 8.0$ Hz), 7.05 (1H, m), 6.99 (1H, m), 4.39 (1H, d, $J(HH) = 6.3$ Hz), 3.44 (1H, m), 3.43 (3H, s), 3.02 (1H, dd, $J(HH) = 6.3$ Hz, $J(HH)$ $= 5.1$ Hz), 1.62 (9H, s). ¹³C NMR (CDCl₃): δ 179.7, 168.6, 160.5, 143.0, 135.5, 133.4, 132.5, 130.6, 130.2, 125.8, 125.7, 124.9, 122.9, 64.0, 49.8, 36.1, 33.2, 30.2. 13C DEPT 135 NMR (CDCl3): *δ* 135.5, 133.4, 132.5, 130.6, 130.2, 125.8, 124.9, 122.9, 64.0, 36.1, 30.2 (all CH), 33.2 (CH2).

1-Methyl-5-(2-(3-tolyl)phenyl)-1*H***-1,4-benzodiazepin-2(3***H***)-one, 7a.** A toluene (15 mL) mixture of **3a** (0.10 g, 0.25 mmol), 3-tolylboronic acid (0.17 g, 1.25 mmol), and potassium carbonate (0.25 g, 1.81 mmol) was stirred under Ar at 110 °C for 18 h. After cooling, the resulting black mixture was filtered over Celite and the fitrate was concentrated in vacuo*.* The residue was taken up in ethyl acetate (10 mL), washed with brine, and dried (MgSO4). Filtration and evaporation of the solvent gave the crude product, which after flash chromatography (5:1 hexane/dichloromethane to 3:1 dichloromethane/ ethyl acetate) afforded an oil of limited purity (0.028 g, purity ca. 80% by 1H NMR). 1H NMR (CDCl3): *δ* 7.49 (1H, m), 7.46 (2H, m), 7.23 (2H, m), 6.90 (5H, m), 6.70 (2H, m), 4.80 (1H, d, $J(HH) = 8.4$ Hz), 3.68 (1H, d, $J(HH) = 10.2$ Hz), 3.10 (3H, s), 2.17 (3H, s) $(C_{23}H_{20}N_2O)$; m/z 341 (MH+, 100%).

X-ray Structure Determination. Data were collected on a Bruker Smart CCD diffractometer at 200 K. Mo K α radiation was used, and the intensities were corrected for Lorentz and polarization effects. An empirical absorption correction was applied using SADABS16 based on the Laue symmetry of the reciprocal space. Relevant crystal and data collection parameters are given in Tables 6 and 7. The structures were solved by direct methods and refined against *F*² with a full matrix least-squares algorithm by using the SHELXTL software package.16 Unless otherwise noted, hydrogen atoms were considered at calculated positions and refined using appropriate riding models. CCDC 281941 (**5d**) and 281942 (**4a**) contain the supplementary crystallographic data for the structures. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC,

(16) Sheldrick, G. M. *SHELXTL*; Bruker Analytical X-ray-Division: Madison, WI.

12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk).

Acknowledgment. We thank CNPq for partial financial support and for scholarships (M.P.S. and V.I.R.).

Supporting Information Available: Tables of full crystal data, atomic coordinates, calculated hydrogen coordinates, anisotropic thermal parameters, and a complete list of bond lengths and angles are available free of charge via the Internet at http:/pubs.acs.org.

OM0506623